Cargando…
CXCL2 combined with HVJ-E suppresses tumor growth and lung metastasis in breast cancer and enhances anti-PD-1 antibody therapy
Breast cancer has a high risk of metastasis; however, no effective treatment has been established. We developed a novel immunotherapy for breast cancer to enhance cytotoxic T lymphocytes against cancer cells using N1-type neutrophils with anti-tumor properties. For this purpose, we combined CXCL2 (C...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Society of Gene & Cell Therapy
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851488/ https://www.ncbi.nlm.nih.gov/pubmed/33575480 http://dx.doi.org/10.1016/j.omto.2020.12.011 |
_version_ | 1783645640424685568 |
---|---|
author | Pan, Yi Chun Nishikawa, Tomoyuki Chang, Chin Yang Tai, Jiayu A. Kaneda, Yasufumi |
author_facet | Pan, Yi Chun Nishikawa, Tomoyuki Chang, Chin Yang Tai, Jiayu A. Kaneda, Yasufumi |
author_sort | Pan, Yi Chun |
collection | PubMed |
description | Breast cancer has a high risk of metastasis; however, no effective treatment has been established. We developed a novel immunotherapy for breast cancer to enhance cytotoxic T lymphocytes against cancer cells using N1-type neutrophils with anti-tumor properties. For this purpose, we combined CXCL2 (CXC chemokine ligand 2) plasmid DNA with inactivated Sendai virus (hemagglutinating virus of Japan)-envelope (HVJ-E). The combination of CXCL2 DNA and HVJ-E (C/H) suppressed the growth of murine breast cancers in orthotopic syngeneic models by enhancing cytotoxic T lymphocytes and inhibited lung metastasis of breast cancer from primary lesions. N1-type neutrophils (CD11b(+) Ly6G(+) FAS(+)) increased in the tumor microenvironment with C/H treatment, and tumor suppression and cytotoxic T lymphocyte activation from C/H was blocked after administrating anti-neutrophil antibodies, which indicates the role of N1-type neutrophils in cancer immunotherapy. We also demonstrated that the anti-tumor activities of C/H treatment were enhanced by the administration of anti-PD-1 antibodies through neutrophil-mediated cytotoxic T lymphocyte activation. Thus, the triple combination of C/H and anti-PD-1 antibody C/H treatment may provide an improvement in cancer immunotherapy. |
format | Online Article Text |
id | pubmed-7851488 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | American Society of Gene & Cell Therapy |
record_format | MEDLINE/PubMed |
spelling | pubmed-78514882021-02-10 CXCL2 combined with HVJ-E suppresses tumor growth and lung metastasis in breast cancer and enhances anti-PD-1 antibody therapy Pan, Yi Chun Nishikawa, Tomoyuki Chang, Chin Yang Tai, Jiayu A. Kaneda, Yasufumi Mol Ther Oncolytics Original Article Breast cancer has a high risk of metastasis; however, no effective treatment has been established. We developed a novel immunotherapy for breast cancer to enhance cytotoxic T lymphocytes against cancer cells using N1-type neutrophils with anti-tumor properties. For this purpose, we combined CXCL2 (CXC chemokine ligand 2) plasmid DNA with inactivated Sendai virus (hemagglutinating virus of Japan)-envelope (HVJ-E). The combination of CXCL2 DNA and HVJ-E (C/H) suppressed the growth of murine breast cancers in orthotopic syngeneic models by enhancing cytotoxic T lymphocytes and inhibited lung metastasis of breast cancer from primary lesions. N1-type neutrophils (CD11b(+) Ly6G(+) FAS(+)) increased in the tumor microenvironment with C/H treatment, and tumor suppression and cytotoxic T lymphocyte activation from C/H was blocked after administrating anti-neutrophil antibodies, which indicates the role of N1-type neutrophils in cancer immunotherapy. We also demonstrated that the anti-tumor activities of C/H treatment were enhanced by the administration of anti-PD-1 antibodies through neutrophil-mediated cytotoxic T lymphocyte activation. Thus, the triple combination of C/H and anti-PD-1 antibody C/H treatment may provide an improvement in cancer immunotherapy. American Society of Gene & Cell Therapy 2020-12-25 /pmc/articles/PMC7851488/ /pubmed/33575480 http://dx.doi.org/10.1016/j.omto.2020.12.011 Text en © 2020 The Author(s) http://creativecommons.org/licenses/by/4.0/ This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Original Article Pan, Yi Chun Nishikawa, Tomoyuki Chang, Chin Yang Tai, Jiayu A. Kaneda, Yasufumi CXCL2 combined with HVJ-E suppresses tumor growth and lung metastasis in breast cancer and enhances anti-PD-1 antibody therapy |
title | CXCL2 combined with HVJ-E suppresses tumor growth and lung metastasis in breast cancer and enhances anti-PD-1 antibody therapy |
title_full | CXCL2 combined with HVJ-E suppresses tumor growth and lung metastasis in breast cancer and enhances anti-PD-1 antibody therapy |
title_fullStr | CXCL2 combined with HVJ-E suppresses tumor growth and lung metastasis in breast cancer and enhances anti-PD-1 antibody therapy |
title_full_unstemmed | CXCL2 combined with HVJ-E suppresses tumor growth and lung metastasis in breast cancer and enhances anti-PD-1 antibody therapy |
title_short | CXCL2 combined with HVJ-E suppresses tumor growth and lung metastasis in breast cancer and enhances anti-PD-1 antibody therapy |
title_sort | cxcl2 combined with hvj-e suppresses tumor growth and lung metastasis in breast cancer and enhances anti-pd-1 antibody therapy |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7851488/ https://www.ncbi.nlm.nih.gov/pubmed/33575480 http://dx.doi.org/10.1016/j.omto.2020.12.011 |
work_keys_str_mv | AT panyichun cxcl2combinedwithhvjesuppressestumorgrowthandlungmetastasisinbreastcancerandenhancesantipd1antibodytherapy AT nishikawatomoyuki cxcl2combinedwithhvjesuppressestumorgrowthandlungmetastasisinbreastcancerandenhancesantipd1antibodytherapy AT changchinyang cxcl2combinedwithhvjesuppressestumorgrowthandlungmetastasisinbreastcancerandenhancesantipd1antibodytherapy AT taijiayua cxcl2combinedwithhvjesuppressestumorgrowthandlungmetastasisinbreastcancerandenhancesantipd1antibodytherapy AT kanedayasufumi cxcl2combinedwithhvjesuppressestumorgrowthandlungmetastasisinbreastcancerandenhancesantipd1antibodytherapy |